Concurrent polatuzumab vedotin and radiotherapy showed no unexpected toxicity in B-cell lymphoma
Concurrent polatuzumab vedotin and radiotherapy was feasible in heavily pretreated aggressive B-cell lymphoma without unexpected acute or subacute toxicity.